FDA Grants Fast Track Designation to PT217 for Extensive Stage Small Cell Lung Cancer
The FDA has granted fast track designation to PT217 for patients with extensive stage small cell lung cancer with disease progression.
Ming Wang Phanes Therapeutics Extensive Stage Small Cell Lung Cancer Es Sclc Lung Cancer Pt217 Phase 1 Skybridge Trial Nct05652686
Source: onclive.com